Publications – TCT 2022 Poster
TCT 2022 Poster
Goldberg S et al.
Looking into recently published survival with GDMT over 2 years, patients with a Carillon Mitral Contour System are doing as well as not having moderate/severe regurgitation. In comparison to other available treatment, the data indicated at least a similar outcome over 2 years.
Join our mailing list for invitations to studies along with company announcements.
*NOTE: The Carillon Mitral Contour System has received CE Mark (0344) and is available for sale in Europe and other countries that recognize CE Mark.
CAUTION: Investigational Device. Limited by United States law to investigational use.